PubMed Health⌕ Search

Biomedical subjects

M Klin

Publications and source records attributed to M Klin.

At least 37 records · Page 2Linked to original sources
PubMed1991

[The effect of erythropoietin treatment on endocrine organ function in patients with terminal-stage kidney failure on hemodialysis].

Eleven hemodialyzed patients with uremia were examined for the effect of erythropoietin (EP) treatment carried out for 3 months on functions of different endocrine organs. EP treatment resulted in a decrease of the initial plasma levels of somatotropin, prolactin, follicle-stimulating and luteinizing hormones. EP treatment being over, there was a decrease in the plasma content of ACTH, cortisol and aldosterone. The treatment with EP was also associated with an insignificant rise of the plasma levels of parathyroid hormone and testosterone. EP treatment did not influence the plasma concentration of calcitonin and 25-OH-D. EP was found to exert no significant effect on the pituitary-thyroid reverse relationship. The 3-month treatment with EP eventuated in plasma renin activity inhibition as well as in an increase of the atrial level of natriuretic peptide in the plasma. EP treatment stimulated insulin secretion and reduced glucagon secretion. Finally, EP decreased the gastrin level and to a less degree the plasma level of pancreatic polypeptide.

Adult↗
PubMed1990

Influence of erythropoietin treatment on follitropin and lutropin response to luliberin and plasma testosterone levels in haemodialyzed patients.

Plasma levels of follitropin (FSH), lutropin (LH) and testosterone (TE) were estimated in 5 anaemic haemodialyzed patients before and after 3 months of erythropoietin treatment (EPO group), in 5 male haemodialyzed patients with a haematocrit value of 33% (which was of the same magnitude as the post-treatment haematocrit value in the EPO group) and in 15 male healthy subjects. After EPO treatment, haematocrit values rose from 23.0 +/- 0.9 to 34.6 +/- 0.75%. EPO treatment induced a significant suppression of basal plasma FSH and LH levels, while plasma TE levels slightly increased. After EPO treatment, the response of plasma FSH and LH to luliberin administration was significantly reduced. As the endocrine profile of EPO-treated patients differed from that of haemodialyzed patients showing a similar haematocrit value, it seems that EPO-induced hormonal changes are not or not only related to improvement of anaemia. Normalization of the pituitary-gonadal feedback in EPO treatment seems to participate in the pathogenesis of improved sexual activity in these patients.

Adult↗
PubMed1990

Influence of erythropoietin treatment on plasma renin activity, aldosterone, vasopressin and atrial natriuretic peptide in haemodialyzed patients.

In 5 haemodialyzed patients the influence of 3 months' erythropoietin (EPO) treatment on plasma renin activity (PRA), aldosterone (Ald), vasopressin (AVP) and atrial natriuretic peptide (ANP) was studied. Results were compared with those obtained in 7 uraemic patients showing a similar haematocrit value as patients after EPO therapy and with those obtained in 10 healthy subjects. EPO treatment did not influence significantly blood pressure but was suppressing PRA and plasma Ald levels, and raising plasma ANP concentrations. EPO treatment was without influence on AVP plasma levels. Data obtained in this study suggest that EPO-induced endocrine alterations are not due to increased blood volume and only partially related to improvement of uraemic anaemia.

Adult↗
PubMed1990

Plasma level of atrial natriuretic peptide in renal venous blood--marker of kidney ischemia?

In 12 patients with unilateral significant renal ischemia plasma levels of atrial natriuretic peptide (ANP) were estimated in renal vein blood of the ischemic (IK) and contralateral kidney (NK) and in arterial blood under supine and upright conditions. Plasma ANP levels in renal vein blood were compared with plasma renin activity (PRA) of the same blood samples. Plasma ANP levels in renal vein blood of the contralateral kidney (87 +/- 9 pg/ml) were significantly lower than in arterial blood (131 +/- 11 pg/ml) and renal vein blood of the ischemic kidney (139 +/- 16 pg/ml). In contrast plasma ANP concentrations in renal vein blood of the ischemic kidney were slightly or markedly higher than in arterial blood. A positive correlation was found between the ratio of plasma ANP in renal vein blood of the IK to that of the NK under supine condition and the respective ratio of PRA. Data presented in this paper suggest the presence of abnormal handling of ANP by an ischemic kidney and that plasma ANP levels in renal vein blood may be a marker of renal ischemia.

Adolescent↗
PubMed1990

[Mechanisms of compensatory hypertrophy of the kidney].

The paper presents the actual state of knowledge on compensatory renal growth. The following problems are discussed: 1) hemodynamical, biochemical and morphological alternations in different models compensatory renal growth, 2) mechanisms of induction and modification kidney growth, 3) hormonal control of kidney growth.

Acute Kidney Injury↗
PubMed1990

Influence of erythropoietin treatment on function of the pituitary-adrenal axis and somatotropin secretion in hemodialyzed patients.

In five hemodialyzed patients the influence of erythropoietin (EPO) treatment for 3 months on function of the pituitary-adrenal feedback and STH secretion was studied. Results were compared with those obtained in 6 hemodialyzed patients (No-EPO group) showing a comparable Hb concentration and Hct value as patients in the EPO group post-treatment and in 15 healthy subjects. EPO treatment was followed by a significant (ACTH and STH) or moderate (cortisol) suppression of basal plasma levels of ACTH, STH and cortisol respectively, and by a significant reduction of the response of plasma concentrations of these hormones to insulin-induced hypoglycemia. As the response of plasma levels of ACTH, STH and cortisol respectively in patients of the EPO group post-treatment differed markedly from that of the No-EPO group with similar Hb and Hct values, it seems that the EPO-induced endocrine alterations are not, at least not exclusively, a consequence of the improvement of anemia. Results presented in this study suggest that EPO treatment influences directly or indirectly the function of endocrine organs.

Adrenocorticotropic Hormone↗
PubMed1989

Endocrine abnormalities in patients with endstage renal failure.

Data presented in this study suggest existence of hyperendorphinism in uraemic patients. This hyperendorphinism may be regarded both as a primary beneficial compensatory mechanism counteracting disturbances of the internal environment, while causing secondary harmful side effects, which contribute to the uraemic state. Erythropoietin treatment of uraemic, haemodialyzed patients is followed by marked endocrine alterations (suppression of plasma levels of STH, ACTH, prolactin, glucagon, aldosterone, cortisol and plasma renin activity, elevation of plasma insulin and atrial natriuretic levels, lack of influence on plasma PTH, CT and AVP). It remains to be clarified whether the erythropoietin induced endocrine alterations are due to correction of the existing anaemia or reflect a specific effect of this hormone.

Endocrine System Diseases↗